Stemolecule CHIR99021
Stemgent

Stemolecule CHIR99021

QTY Cat # Size Unit Price
04-0004 2 mg $276.00
04-0004-10 10 mg $1,081.00
04-0004-02 2mg (10mM) $324.00

* Prices listed are in USD. Taxes, shipping & handling not included. Contact us for bulk pricing.

Add to My Quote
Have questions? Message Us

Overview

The aminopyrimidine CHIR99021 is the most selective inhibitor of glycogen synthase kinase 3β (GSK-3β) reported to date1,2. Unlike other potent inhibitors of GSK-3, CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs3. Along with the elimination of differentiation-inducing signaling from mitogen-activated protein kinases, using CHIR99021 to block the activity of GSK-3β enables the self-renewal of embryonic stem cells4.

Also available as a convenient 10 mM solution in DMSO (Cat. No. 04-0004-02)

Specifications

Product Name: Stemolecule CHIR99021

Catalog Number: 04-0004

Size:

  • 2 mg (Cat. No. 04-0004)
  • 10 mg (Cat. No. 04-0004-10)
  • 2 mg in 10 mM DMSO solution  (2 mg in 429.8 μl) (Cat. No. 04-0004-02)

Alternate Name(s): 6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2 pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile

Chemical Formula: C22H18Cl2N8

Molecular Weight: 465.34

CAS Number: 252917-06-9

Purity: Greater than 95 % by HPLC analysis

Formulation: Off-white solid (04-0004, 04-0004-10) or colorless to pale yellow liquid (04-0004-02)

Storage and Stability: Store powder at 4 °C protected from light. Information about the stability of Stemolecules in solution is largely not available. As a general guideline, we recommend that stock solution be freshly made and stored in aliquots at −20 °C. The effect of storage of stock solutions should be verified for each application.

Quality Control: The purity of CHIR99021 was determined by HPLC analysis. The accurate mass was determined by mass spectrometry. Cellular toxicity of CHIR99021 was tested on pluripotent stem cells.

Documents

SDS-04-0004-02-CHIR099021_in_solution-v1.2 SDS-04-0004_04-0004-10-CHIR099021-v1.4 SPEC-04000410 SPEC-04000402 SPEC-040004
References
  1. Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., and Brivanlou, A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10: 55-63 (2004).
  2. Besser, D. (2004) Expression of nodal, lefty-a, and lefty-B in undifferentiated human embryonic stem cells requires activation of Smad 2/3. J Biol Chem 279: 45076-45084 (2004).
  3. Ying, Q.L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., and Smith, A. The ground state of embryonic stem cell self renewal. Nature 453: 519-523 (2008).
  4. Polychronopoulos, P., Magiatis, P., Skaltsounis, A.L., Myrianthopoulos, V., Mikros, E., Tarricone, A., Musacchio, A., Roe, S.M., Pearl, L., Leost, M., Greengard, P., and Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 47: 935-946 (2004).